内皮激活与应激指数(EASIX)作为预测芦可替尼治疗类固醇难治性急性移植物抗宿主病失败的生物标志物
该研究纳入6个加拿大中心的78例接受芦可替尼治疗的类固醇难治性急性移植物抗宿主病患者,评估EASIX对芦可替尼失败的预测价值。主要终点为无失败生存(FFS),EASIX在芦可替尼起始时≥1.11的患者6个月FFS为17%,低于低EASIX患者的54%(HR 2.75,95%CI 1.23-6.15,p=0.014)。基于肠道aGvHD、4级aGvHD和高EASIX的三因素风险评分可分层6个月FFS。
要点
- 芦可替尼起始时高EASIX(≥1.11)与较低的6个月FFS相关(17% vs 54%,HR 2.75)。
- 三因素风险评分(肠道aGvHD、4级aGvHD、高EASIX)可将6个月FFS分为85.7%、28.0%和11.0%。
- 作者提出对高EASIX患者可考虑在芦可替尼治疗基础上预防性增加其他治疗干预。
核心结论
- 高EASIX可预测类固醇难治性急性移植物抗宿主病患者芦可替尼治疗失败的风险,独立于肠道aGvHD和4级aGvHD。
- 作者提出对高EASIX患者可考虑在芦可替尼治疗基础上预防性增加其他治疗干预。
研究设计与样本
- 研究纳入来自6个加拿大中心的78例接受芦可替尼治疗的类固醇难治性急性移植物抗宿主病患者。
- 主要终点为无失败生存(FFS),EASIX评分在预设时间点计算,并使用递归分区法进行二分类。
- 基于关键变量开发了芦可替尼失败风险评分。
主要发现
- 芦可替尼起始时,76%的患者为3-4级aGvHD。
- 最佳总体缓解率为75%;58%的患者发生芦可替尼失败,6个月FFS为25.7%。
- EASIX随时间逐渐升高,即使在芦可替尼治疗后也是如此(p < 0.001)。
- 芦可替尼起始时高EASIX(≥1.11)的患者6个月FFS为17%,低于低EASIX患者的54%(HR 2.75,95%CI 1.23-6.15,p = 0.014)。
- 三因素芦可替尼失败风险评分(肠道aGvHD、4级aGvHD、芦可替尼起始时高EASIX)将患者按6个月FFS分层:评分0(n=28)为85.7%,评分1(n=25)为28.0%,评分≥2(n=34)为11.0%(HR 2.25,95%CI 1.42-3.55,p < 0.001)。
关键数值与推荐
- 芦可替尼起始时高EASIX定义为≥1.11。
- 三因素风险评分包括:肠道aGvHD、4级aGvHD、芦可替尼起始时高EASIX。
- 风险评分0、1、≥2对应的6个月FFS分别为85.7%、28.0%、11.0%。
临床怎么用
- 作者提出对高EASIX患者可考虑在芦可替尼治疗基础上预防性增加其他治疗干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steroid-refractory acute graft-versus-host disease (SR-aGvHD) remains a significant challenge after haematopoietic cell transplantation (HCT). While ruxolitinib (RUX) has shown efficacy for SR-aGvHD, failure predictors are poorly defined. We assessed 78 patients from six Canadian centres who received RUX for SR-aGvHD. Failure-free survival (FFS) was the primary end-point. Endothelial activation and stress index (EASIX) scores were calculated at defined time points, dichotomized using recursive partitioning. A risk score for RUX failure was developed based on key variables. At RUX initiation, 76% of patients had grade 3-4 aGvHD. The best overall response rate was 75%; 58% experienced RUX failure, while the 6-month FFS was 25.7%. EASIX gradually increased over time even after RUX (p < 0.001). Patients with high EASIX at RUX ≥1.11 had a lower FFS at 6 months (17%) than the patients with low EASIX (54%) (hazard ratio [HR] 2.75 [95%CI 1.23-6.15], p = 0.014). A three-factor RUX failure risk score-gut aGvHD, grade 4 aGvHD and high EASIX at RUX start-stratified patients by 6-month FFS rates: 85.7%, 28.0% and 11.0% for score 0 (n = 28), 1 (n = 25) and ≥2 (n = 34) (HR 2.25[1.42-3.55], p < 0.001). High EASIX can predict the risk of RUX failure in addition to gut aGvHD and grade 4 aGvHD. We propose to add other therapeutic interventions to RUX therapy pre-emptively to high EASIX patients.
引用
- Rodriguez-Rodriguez S, Desai N, Chen C, et al. Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment. Br J Haematol. 2025. PMID: 40947302. doi:10.1111/bjh.70146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。